Biological Information
Background Information:
Thromboxane A2 (TxA2) is a potent platelet activator which serves to amplify the response to weak agonists such as ADP, epinephrine, and low concentrations of collagen and thrombin. Upon cell activation, phospholipase released arachidonic acid is converted by cyclooxygenase to unstable endoperoxides (PGG2 or PGH2) which are in turn converted to TxA2 by thromboxane synthase. The endoperoxides and TxA2 generated by aggregating platelets could produce a profound vasoconstriction largely restricted to the area of the vessel immediately adjacent to the platelet plug; e.g., vasospasm associated with coronary or cerebral infarction. An enhanced production of TxA2 is associated with the pathogenesis of various thrombotic and ischemic disorders.
Family:
CYP450
Sub Family:
CYP5/7/8
Protein Name:
Thromboxane Synthase
Uniprot Number:
P24557
Protein Aliases:
cytochrome P450, family 5, subfamily A, polypeptide 1
Gene Name:
TBXAS1
Gene ID:
6916
Gene Aliases:
CYP5|CYP5A1|THAS|TXS|TXAS|TS
Accession Number:
NM_001061
Organism:
Human
Construct Details:
Endogenous
Assay Information
Assay Type:
Biochemical
Assay Sub Type:
Enzymatic
Functional Mode:
Antagonist
Detection Method:
EIA
Measured Response:
Absorbance
Testing Information
Procedure Summary:
Human platelet thromboxane A2 synthase is used. Test compound and/or vehicle is preincubated with 20 μg/ml enzyme‡ in Tris-HCl buffer pH 7.4 for 15 minutes at 25⁰C. The reaction is initiated by addition of 10 μM prostaglandin H2 for another 3 minute incubation period and terminated by further addition of 1N HCl. An aliquot is removed and determine the amount of thromboxane B2 formed spectrophotometrically by EIA kit. Compounds are screened at 10 μM.
Substrate:
10 µM PGH₂
Incubation:
3 min at 25°C
Control Inhibitor:
1-(7-Carboxyheptyl)-Imidazole
Criteria For Significance:
≥ 50% of max stimulation or inhibition
Test Concentration / Dose:
Suggested concentration for initial testing is 10 uM
Test Sample Requirements:
Minimum for 1) Screen: 25 μl of 10 mM stock -OR- 1 mg (pre-weighed). 2) Dose Response: 60 μl of 10 mM stock -OR- 1 mg (pre-weighed).
Minimum Order Quantity:
2
Turnaround Time
Standard:
15 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Inflammation/Allergy
Adverse / Beneficial Action:
Inhibitors of TxA2 biosynthesis may be of benefit in the treatment of ischemic heart diseases, cerebral infarction, arteriosclerosis and diabetic disorders.
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei
RELATED SOLUTIONS